

糖苷轉化微脂體

主要領域


奈米藥物/ 癌症治療

產品/技術簡介

- 糖苷轉化微脂體(GSL)藉由提升抗癌藥物在微脂體中的承載力、穩定滯留性及其安全運輸性來增加奈米藥物的功效。

原理

- 此技術利用化學修飾抗癌藥物上的糖苷轉換官能基 (-G) 以控制藥物在親脂的狀態下(-G^L)可有效地負載於微脂體內、且以親水的狀態(-G^W)穩定滯留在微脂體的水相中心。



可逆性糖苷轉化之概念

應用

- 此糖苷轉化技術透過穩定負載藥物於微脂體中，促進抗癌藥物的運輸，提供更佳效力以及安全性的抗癌治療選擇。

專利現況

- 已核准: 美國專利及商標局，中華民國經濟部智慧財產局
- 審查中: 歐洲專利局，中國大陸國家知識產權局
- 可逆性糖苷轉化之概念

Glycosidic Switch Liposomes


Research Area Nanomedicines / Cancer treatment

● Technical novelty

The Glycosidic Switch Liposome (GSL) platform increases the power of nanomedicines by facilitating active loading, stable retention, and safe delivery of potent drugs in liposomes.

● Principle

This is chemically achieved via a glycosidic switch (-G), which can be reversibly attached to drugs and controllably interchanged between a lipophilic state (-GL) for efficient loading and a hydrophilic state (-G^W) for stable retention of drugs in the liposomal aqueous core.



● Advantages

The platform technology provides a general method for different potent drugs loading with higher encapsulation efficiency, higher drug retention, and multiple drugs loading.

● Application

The glycosidic switch could facilitate retention, delivery, and safety of a large range of highly potent hydrophobic anticancer drugs and subsequently provide more effective anticancer therapies

● Patent status

Granted: United States, Taiwan

Pending: European Patent Office, China

Glycosidic Switch Liposomes

計畫主持人 Project PI



Steve Roffler,
羅傳倫



呂玉玲



林俊宏

計畫成員 Member



林偉琪



楊世弘



金主愛



Tran Thi My Trieu



何冠蓁



Daniel Lin



劉昶承

Contact : Steve Roffler, PhD
Distinguished Research Fellow IBMS, Academia Sinica
886-2-2652-3079
sroff@ibms.sinica.edu.tw

